Guggenheim Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Ionis Pharmaceuticals (NASDAQ:IONS) and raises the price target from $64 to $70.
August 02, 2024 | 7:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Ionis Pharmaceuticals and raises the price target from $64 to $70.
The Buy rating and increased price target from a reputable analyst at Guggenheim is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100